PHARMACOECONOMIC ANALYSIS OF HIVAIDS MANAGEMENT PHARMACY

Abstract

The human 
immunodeficiency virus (HIV) is becoming 
more widespread worldwide. Although it 
has been demonstrated that pharmacist 
interventions enhance the health outcomes 
of individuals living with HIV/AIDS 
(PLWHA), it is unclear how these activities 
will affect the economy. As a result, our 
goal is to compile and evaluate the data in a 
methodical manner about the financial 
implications of pharmacist care for 
PLWHA.
Methods: A thorough search of the 
Cochrane Library, the databases CINAHL 
Plus, EMBASE, Scopus, and IPA via 
ProQuest were conducted. The review 
contained original research assessing the 
financial impact of pharmacist-managed 
services for PLWHA.
The Consolidated Health Economic 
Evaluation Reporting Standard (CHEERS) 
checklist was used to evaluate the economic 
studies' quality.
Findings: Four of the 4206 citations that 
were found through a database search 
satisfied the eligibility requirements. One 
study was carried out in a community 
pharmacy, while three others were carried 
out in an outpatient hospital environment. 
Targeted motivational education, 
pharmaceutical treatment, health screening 
for opportunistic infections, and specialist 
referrals were among the "pharmacistmanaged services" categories. Two of the 
four studies that made up the economic 
evaluation provided full economic 
evaluations and were deemed to be of 
average quality. Pharmacist services 
resulted in cost savings of (51.29 to 165.74 
in 2021 USD$) per person per year, 18.5 
hours saved per patient annually, and a 
reduced cost of producing 12 years of 
quality-adjusted life years as compared to 
conventional care. Furthermore, the 
pharmacist service's benefit-to-cost ratio 
was 2.51:1.
Conclusions: The services run by 
pharmacists showed the financial 
sustainability of enhancing the general 
health outcomes of PLWHAs. To ascertain 
the long-term cost-effectiveness of these 
services, however, controlled, high-quality 
real-world economic studies are necessary, 
considering the pharmacist's expanding 
involvement in the health care team 
overseeing PLWHA.